| (Senior) Medical Science Liaison | Boehringer Ingelheim | Taipei, Taiwan | 2026-07-11 |
| Regulatory Affairs & Pharmacovigilance Manager, ASKAN | Boehringer Ingelheim | Singapore, Singapore | 2026-07-11 |
| Medical Affairs Lead Stroke,HP ROPU ASKAN | Boehringer Ingelheim | Singapore, Singapore | 2026-07-11 |
| Medical Science Liaison | Boehringer Ingelheim | Poland | 2026-07-11 |
| (Sr.)Clinical Trial Manager - CRM | Boehringer Ingelheim | Shanghai, China | 2026-07-11 |
| Head of TA Medicine, Oncology | Boehringer Ingelheim | Shanghai, China | 2026-07-11 |
| Post Doctoral - Drug Metabolism and Clinical Safety | Boehringer Ingelheim | Athens, United States | 2026-07-11 |
| (Senior) Medical Science Liaison | Boehringer Ingelheim | Taichung, Taiwan | 2026-07-11 |
| Sr. AD, Patient & Community Clinical Educator (PaCE) - ILD - West Plains | Boehringer Ingelheim | Dallas, United States | 2026-07-11 |
| Medical Advisor Head Office - Mumbai | Boehringer Ingelheim | Mumbai, India | 2026-07-11 |
| Medical Representative, UPC | Boehringer Ingelheim | Bangkok, Thailand | 2026-07-11 |
| Medical Science Liaison | Boehringer Ingelheim | Al Aแธฉmadฤซ, Kuwait | 2026-07-11 |
| Director, Medical Affairs Strategy Team Member - Respiratory (Hybrid) | Boehringer Ingelheim | United States | 2026-07-11 |
| Director, Medical Affairs Strategy Team Member - Pulmonary ILD (Hybrid) | Boehringer Ingelheim | United States | 2026-07-11 |
| Senior Associate Director, Medical Affairs Strategy Team Member - Respiratory (Hybrid) | Boehringer Ingelheim | United States | 2026-07-11 |
| Senior Associate Director, Medical Affairs Strategy Team Member - Pulmonary ILD (Hybrid) | Boehringer Ingelheim | United States | 2026-07-11 |
| Medical Science Liaison - CRM | Boehringer Ingelheim | Zhengzhou, China | 2026-07-11 |
| (Sr.) Medical Science Liaison - CRM | Boehringer Ingelheim | Shenyang, China | 2026-07-11 |
| Clinical Trial Budget Manager (Hybrid/On-site) | Boehringer Ingelheim | United States | 2026-07-11 |
| (Senior) Medical Science Liaison | Boehringer Ingelheim | Taipei, Taiwan | 2026-07-11 |
| Drug Safety Specialist/Non-Line Manager or Staff/Patient Safety and Pharmacovigilance | Boehringer Ingelheim | Shinagawa, Japan | 2026-07-11 |
| (Senior) Clinical Program Lead | Boehringer Ingelheim | Germany | 2026-07-11 |
| Medical Science Liaison - North zone Delhi | Boehringer Ingelheim | Delhi, India | 2026-07-11 |
| Regional Clinical Trial Manager | Boehringer Ingelheim | Buenos Aires, Argentina | 2026-07-11 |
| Responsable qualitรฉ mรฉdical adjoint (H/F) - CDD 6 mois | Boehringer Ingelheim | Reims, France | 2026-07-11 |
| ้ซ่ฅๆฅญๅๅฐๅก (ๅๅ) - CRM / Medical Sales Specialist, North - CRM | Boehringer Ingelheim | Taipei, Taiwan | 2026-07-11 |
| EXT Medical Representative - region ฤechy | Boehringer Ingelheim | Republic, United States | 2026-07-11 |
| EXT Medical Representative - Plzeลsko a Zรกpadnรญ ฤechy | Boehringer Ingelheim | Republic, United States | 2026-07-11 |
| EXT Medical Representative - region Morava, Slezsko | Boehringer Ingelheim | Republic, United States | 2026-07-11 |
| EXT Medical Representative - region Praha | Boehringer Ingelheim | Republic, United States | 2026-07-11 |
| Medical Science Liaison in Ha Noi | Boehringer Ingelheim | Vietnam | 2026-07-11 |
| Manager, Medical Affairs | Boehringer Ingelheim | Shanghai, China | 2026-07-11 |
| Oncology Medical Science Liaison Northern California and Nevada | Boehringer Ingelheim | San Francisco, United States | 2026-07-11 |
| Medical Representative in Ha Noi | Boehringer Ingelheim | Vietnam | 2026-07-11 |
| Medical Affairs Lead, ILD | Boehringer Ingelheim | Seoul, South Korea | 2026-07-11 |
| (Senior) Patient Safety Physician, Medical Safety Physician - Oncology | Boehringer Ingelheim | United States | 2026-07-11 |
| ้ซ่ฅๆฅญๅๅฐๅก (ๅๅ) - GP / Medical Sales Specialist, North - GP | Boehringer Ingelheim | Taipei, Taiwan | 2026-07-11 |
| (Sr.) Medical Science Liaison - Inflammation | Boehringer Ingelheim | Beijing, China | 2026-07-11 |
| (Sr.) Medical Science Liaison - Inflammation | Boehringer Ingelheim | Guangzhou, China | 2026-07-11 |
| Medical Representative - GH | Boehringer Ingelheim | Klang, Malaysia | 2026-07-11 |
| Lead Patient Safety Physician - CRM | Boehringer Ingelheim | United States | 2026-07-11 |
| Executive Medical Director, Clinical Development Lead - Oncology - Lung & Head/Neck Cancers | GSK | Baar, Switzerland | 2026-07-11 |
| Medical Representative (Tuguegarao/Isabela) | GSK | United Kingdom | 2026-07-11 |
| Senior Medical Scientific Liaison | AstraZeneca | Manila, Philippines | 2026-07-11 |
| Medical Science Liason | Ferring Pharmaceuticals | Canada | 2026-07-11 |
| People leader for a department of medical specialists in Obesity & Cardiometabolic Health | Novo Nordisk | Gladsaxe, Denmark | 2026-07-11 |
| Medical Liaison - Obesity & Liver Health - Western Pennsylvania | Novo Nordisk | Pittsburgh, United States | 2026-07-11 |
| Europe Region Lead, Diversity & Inclusion in Clinical Trials (DICT) | Sanofi | Gentilly, France | 2026-07-11 |
| alternance 12 mois โ projets mรฉdico-sociaux | Sanofi | Montpellier, France | 2026-07-11 |
| Global Head Medical Strategy, Operations & Governance | Ipsen | France | 2026-07-11 |